Pneumonia risk in diabetic patients to be reduced by SGLT2 inhibitors

Diabetic patients are 3 times more likely to die with flu and pneumonia. Yet, only one third of them ever get a simple, safe pneumonia shot. Pneumonia is a serious illness for anyone, but highly riskier with a history of diabetics.

Patients with type 2 diabetes using SGLT2 inhibitors are at a significantly lower risk of pneumonia and pneumonia mortality versus those using DPP4 Iinhibitors, reveals a reent study. The study was published in the Journal of Clinical Endocrinology and Metabolism on 08 November 2021.

Sodium glucose co-transporter 2 inhibitors (SGLT2is) are the latest class of glucose-lowerinf agents that have shown to reduce pneumonia risk in clinical trials. However, not much is known about the real-world effectiveness of SGLT2is on the risk of pneumonia.

To determine the same, Ching-Lung Cheung, The University of Hong Kong, Hong Kong SAR, China, and the team aimed to investigate the associations between SGLT2is use and the risk of pneumonia and pneumonia mortality versus dipeptidyl peptidase-4 inhibitors (DPP4is) using an electronic medical database in Hong Kong in a retrospective cohort study.

For more information check out the full story on the link below:

SGLT2 inhibitors use tied to lower pneumonia risk in diabetics: Study